<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Biology and Life Sciences : Anatomy : Body Fluids :" exact="Blood" post=": Blood Serum: Immune Serum : Medicine and Health"/>
 <result pre="Life Sciences : Anatomy : Body Fluids : Blood :" exact="Blood" post="Serum: Immune Serum : Medicine and Health Sciences :"/>
 <result pre="Medicine and Health Sciences : Anatomy : Body Fluids :" exact="Blood" post=": Blood Serum: Immune Serum : Biology and Life"/>
 <result pre="Health Sciences : Anatomy : Body Fluids : Blood :" exact="Blood" post="Serum: Immune Serum : Biology and Life Sciences :"/>
 <result pre="Biology and Life Sciences : Physiology : Body Fluids :" exact="Blood" post=": Blood Serum: Immune Serum : Medicine and Health"/>
 <result pre="Life Sciences : Physiology : Body Fluids : Blood :" exact="Blood" post="Serum: Immune Serum : Medicine and Health Sciences :"/>
 <result pre="Medicine and Health Sciences : Physiology : Body Fluids :" exact="Blood" post=": Blood Serum: Immune Serum : Biology and Life"/>
 <result pre="Health Sciences : Physiology : Body Fluids : Blood :" exact="Blood" post="Serum: Immune Serum : Biology and Life Sciences :"/>
 <result pre="Immune System Proteins: Antibodies : Medicine and Health Sciences :" exact="Infectious" post="Diseases: Superinfection : Biology and Life Sciences : Anatomy"/>
 <result pre=": Biology and Life Sciences : Anatomy : Body Fluids:" exact="Blood" post=": Medicine and Health Sciences : Anatomy : Body"/>
 <result pre=": Medicine and Health Sciences : Anatomy : Body Fluids:" exact="Blood" post=": Biology and Life Sciences : Physiology : Body"/>
 <result pre=": Biology and Life Sciences : Physiology : Body Fluids:" exact="Blood" post=": Medicine and Health Sciences : Physiology : Body"/>
 <result pre=": Medicine and Health Sciences : Physiology : Body Fluids:" exact="Blood" post=": Research and Analysis Methods : Immunologic Techniques :"/>
 <result pre=": Body Fluids: Blood : Research and Analysis Methods :" exact="Immunologic" post="Techniques : Immunoassays: Enzyme-Linked Immunoassays : Biology and life"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Orthomyxoviruses : Influenza viruses: Influenza A virus"/>
 <result pre=": Animal Studies : Experimental Organism Systems : Model Organisms:" exact="Mouse" post="Models : Research and Analysis Methods : Model Organisms:"/>
 <result pre="Mouse Models : Research and Analysis Methods : Model Organisms:" exact="Mouse" post="Models : Research and Analysis Methods : Animal Studies"/>
 <result pre=": Animal Studies : Experimental Organism Systems : Animal Models:" exact="Mouse" post="Models : Medicine and Health Sciences : Health Care"/>
 <result pre="SD, United States of America[2], Department of Medicine, Division of" exact="Infectious" post="Diseases, University of Tennessee Health Science Center, Memphis, TN,"/>
 <result pre="used in this manuscript was the subject of a US" exact="Patent" post="#6063386 entitled Recombinant Multivalent M Protein Vaccines, which has"/>
 <result pre="subject of a US Patent #6063386 entitled Recombinant Multivalent M" exact="Protein" post="Vaccines, which has subsequently expired. Additional patents related to"/>
 <result pre="medium, provided the original author and source are credited.pone.0235139.pdf Abstract" exact="Viral" post="infections complicated by a bacterial infection are typically referred"/>
 <result pre="provided the original author and source are credited.pone.0235139.pdf Abstract Viral" exact="infections" post="complicated by a bacterial infection are typically referred to"/>
 <result pre="and source are credited.pone.0235139.pdf Abstract Viral infections complicated by a" exact="bacterial infection" post="are typically referred to as coinfections or superinfections. Streptococcus"/>
 <result pre="source are credited.pone.0235139.pdf Abstract Viral infections complicated by a bacterial" exact="infection" post="are typically referred to as coinfections or superinfections. Streptococcus"/>
 <result pre="to penicillin. One approach to improve the outcome of these" exact="infections" post="is to use passive immunization targeting GAS. To test"/>
 <result pre="Data Availability All relevant data are within the paper. Introduction" exact="Infection" post="with influenza A virus (IAV) creates a permissive environment"/>
 <result pre="with influenza A virus (IAV) creates a permissive environment for" exact="secondary" post="bacterial infections (often referred to as superinfections), which significantly"/>
 <result pre="influenza A virus (IAV) creates a permissive environment for secondary" exact="bacterial infections" post="(often referred to as superinfections), which significantly increases the"/>
 <result pre="A virus (IAV) creates a permissive environment for secondary bacterial" exact="infections" post="(often referred to as superinfections), which significantly increases the"/>
 <result pre="[1]. Streptococcus pyogenes (the group A Streptococcus, GAS) typically causes" exact="pharyngitis" post="but also can cause more serious invasive GAS infections"/>
 <result pre="causes pharyngitis but also can cause more serious invasive GAS" exact="infections" post="(iGAS) such as bacteremia, toxic shock syndrome, necrotizing fasciitis,"/>
 <result pre="cause more serious invasive GAS infections (iGAS) such as bacteremia," exact="toxic shock syndrome," post="necrotizing fasciitis, and IAV superinfections. An analysis of lung"/>
 <result pre="invasive GAS infections (iGAS) such as bacteremia, toxic shock syndrome," exact="necrotizing fasciitis," post="and IAV superinfections. An analysis of lung biopsies from"/>
 <result pre="50 million deaths attributed to influenza [2]. IAV increases host" exact="susceptibility to" post="secondary bacterial infections by a variety of mechanisms. Most"/>
 <result pre="deaths attributed to influenza [2]. IAV increases host susceptibility to" exact="secondary" post="bacterial infections by a variety of mechanisms. Most research"/>
 <result pre="attributed to influenza [2]. IAV increases host susceptibility to secondary" exact="bacterial infections" post="by a variety of mechanisms. Most research related to"/>
 <result pre="to influenza [2]. IAV increases host susceptibility to secondary bacterial" exact="infections" post="by a variety of mechanisms. Most research related to"/>
 <result pre="these studies, murine models of IAV-GAS superinfection show that IAV" exact="infection" post="significantly enhances the virulence of GAS [7–9]. In addition,"/>
 <result pre="vaccination of mice against IAV provides significant protection against GAS" exact="secondary" post="infections indicating a specific role for the virus in"/>
 <result pre="of mice against IAV provides significant protection against GAS secondary" exact="infections" post="indicating a specific role for the virus in enhancing"/>
 <result pre="indicating a specific role for the virus in enhancing host" exact="susceptibility to" post="superinfection [10, 11]. Finally, epidemiological studies support the idea"/>
 <result pre="and particularly influenza, increase the incidence of iGAS diseases including" exact="pneumonia" post="[3, 12]. Many antibiotics, including penicillin, are effective against"/>
 <result pre="and January 2011, 14 of 19 patients with an iGAS" exact="disease" post="also had an IAV infection; ten died, even though"/>
 <result pre="Finally, it is estimated that while only 12% of iGAS" exact="infections" post="involve the lower respiratory tract [15], 38% are fatal"/>
 <result pre="estimated that while only 12% of iGAS infections involve the" exact="lower" post="respiratory tract [15], 38% are fatal [16]. Thus, while"/>
 <result pre="that while only 12% of iGAS infections involve the lower" exact="respiratory" post="tract [15], 38% are fatal [16]. Thus, while GAS"/>
 <result pre="CDC toxins may be good candidates for passive immunotherapy targeting" exact="bacterial" post="pathogens associated with IAV superinfections. While the development of"/>
 <result pre="murine model of IAV-GAS superinfection. Materials and methods Bacterial and" exact="viral" post="isolates and culture conditions S. pyogenes strain MGAS315 (serotype"/>
 <result pre="was propagated for 72 hours at 35°C in the allantoic" exact="cavities" post="of 10-day-old embryonated chicken eggs [24, 29]. Viral RNA"/>
 <result pre="the allantoic cavities of 10-day-old embryonated chicken eggs [24, 29]." exact="Viral" post="RNA was extracted, reverse transcribed, and whole genome sequence"/>
 <result pre="analyses were used to confirm the genetic makeup of the" exact="viral" post="preparation. Further characterization of the virus included calculating the"/>
 <result pre="characterization of the virus included calculating the median tissue culture" exact="infectious" post="dose (TCID50) in Madin-Darby Canine Kidney (MDCK) cells. Polyclonal"/>
 <result pre="the median tissue culture infectious dose (TCID50) in Madin-Darby Canine" exact="Kidney" post="(MDCK) cells. Polyclonal antiserum A recombinant hexavalent M protein"/>
 <result pre="the adjuvant Montanide ISA 50 (Seppic Inc; Fairfield, New Jersey)." exact="Adult" post="12-week old rabbits were kept in individual cages with"/>
 <result pre="Ruth Bakker (D.V.M.) provided all animal care and handling training." exact="Female" post="(6 to 8-week-old) BALB/c mice were purchased from Jackson"/>
 <result pre="up to day 9 after infection; which overlaps with GAS" exact="infection" post="on day 7[33]. Mice were lightly anesthetized with 2.5%"/>
 <result pre="isoflurane and IAV or GAS was given intranasally (100 μl" exact="total" post="volume). Intranasal administration was performed by pipetting small droplets"/>
 <result pre="was recorded daily. Endpoint criteria included extreme clinical signs of" exact="infection" post="(huddling, hunched posture, ruffled fur, tachypnea), severe hypothermia as"/>
 <result pre="signs of infection (huddling, hunched posture, ruffled fur, tachypnea), severe" exact="hypothermia" post="as indicated by a temperature of 34°C (~4.5°C below"/>
 <result pre="or more of these symptoms were immediately euthanized and the" exact="infection" post="was considered lethal. The total number of mice used"/>
 <result pre="were immediately euthanized and the infection was considered lethal. The" exact="total" post="number of mice used in the study was 138."/>
 <result pre="SLO toxin was serially diluted 2-fold with PBS (50 μl" exact="total" post="volume) in a 96-well flat bottom plate. Then, 50"/>
 <result pre="was determined with GraphPad Prism. GAS quantification in mouse tissues" exact="Mouse" post="tissue samples were collected 24 hours after GAS inoculation"/>
 <result pre="samples were collected 24 hours after GAS inoculation (day 8)." exact="Blood" post="was collected from the submandibular vein of each animal"/>
 <result pre="1 mL Melon Gel column, as per manufacturer’s instructions (Thermo" exact="Fisher" post="Scientific; Rockford, IL). All purified IgG was immediately buffer"/>
 <result pre="mg/mL in PBS using 40 kDa Zeba spin columns (Thermo" exact="Fisher" post="Scientific). IgG fractionation was verified by SDS-PAGE and concentrations"/>
 <result pre="Table 1) indicating the sera contained neutralizing antibodies. 10.1371/journal.pone.0235139.t001Table 1" exact="Hemolytic" post="activity of SLO in the presence of serum. Serum"/>
 <result pre="M protein To determine if prophylactic immunotherapy can decrease the" exact="bacterial" post="burden among IAV-GAS superinfected mice, we quantified GAS in"/>
 <result pre="with either antisera to SLO or the M protein was" exact="lower" post="compared to those treated with non-immune sera (p &amp;lt;"/>
 <result pre="as macrophages and neutrophils [36–40]. Passive antibody treatment can decrease" exact="disease" post="by two or more mechanisms. First, antibodies can promote"/>
 <result pre="In this regard, serotype-specific opsonic antibodies to the cell wall" exact="localized" post="M protein have been known for decades to be"/>
 <result pre="which can induce caspase-dependent apoptosis in neutrophils, macrophages [37], and" exact="epithelial" post="cells [38]. Antibody-mediated neutralization of SLO [42] can decrease"/>
 <result pre="containing other GAS antigens) induced non-opsonizing SLO-specific antibodies and decreased" exact="pharyngitis" post="[44]. Thus, the antisera to the M protein and"/>
 <result pre="clinical success using IVIG to treat iGAS diseases, especially streptococcal" exact="toxic shock syndrome" post="[51, 53, 54]; however, definitive results from robust clinical"/>
 <result pre="using IVIG to treat iGAS diseases, especially streptococcal toxic shock" exact="syndrome" post="[51, 53, 54]; however, definitive results from robust clinical"/>
 <result pre="as a passive vaccine in a murine model of iGAS" exact="infection" post="compared to IVIG [58]. These results support the idea"/>
 <result pre="Passive antibody therapy has been successfully used to treat toxin-mediated" exact="bacterial diseases" post="including diphtheria, tetanus, botulism, and Clostridium difficile infections [60]."/>
 <result pre="toxin-mediated bacterial diseases including diphtheria, tetanus, botulism, and Clostridium difficile" exact="infections" post="[60]. These diseases result largely from the activity of"/>
 <result pre="the first to assess efficacy in the context of a" exact="viral" post="superinfection. Previous studies showed that opsonic antisera to a"/>
 <result pre="however, there has been less success in treating established iGAS" exact="infections" post="using passive immunotherapy. While an active vaccine against GAS"/>
 <result pre="is an ideal outcome, many successful vaccines do not abolish" exact="disease" post="including the pneumococcal, Hib, and influenza vaccines [71–74]. Therefore,"/>
 <result pre="influenza pandemics. References References 1MorensDM, TaubenbergerJK, FauciAS. Predominant role of" exact="bacterial" post="pneumonia as a cause of death in pandemic influenza:"/>
 <result pre="pandemics. References References 1MorensDM, TaubenbergerJK, FauciAS. Predominant role of bacterial" exact="pneumonia" post="as a cause of death in pandemic influenza: implications"/>
 <result pre="pandemic influenza: implications for pandemic influenza preparedness. The Journal of" exact="infectious diseases." post="2008;198(7):962–70. Epub 2008/08/20. 10.1086/59170818710327 2MorensDM, FauciAS. The 1918 influenza"/>
 <result pre="influenza pandemic: insights for the 21st century. The Journal of" exact="infectious diseases." post="2007;195(7):1018–28. Epub 2007/03/03. 10.1086/511989 .17330793 3HerreraAL, HuberVC, ChausseeMS. The"/>
 <result pre="Epub 2007/03/03. 10.1086/511989 .17330793 3HerreraAL, HuberVC, ChausseeMS. The Association between" exact="Invasive" post="Group A Streptococcal Diseases and Viral Respiratory Tract Infections."/>
 <result pre="3HerreraAL, HuberVC, ChausseeMS. The Association between Invasive Group A Streptococcal" exact="Diseases" post="and Viral Respiratory Tract Infections. Frontiers in microbiology. 2016;7:342"/>
 <result pre="ChausseeMS. The Association between Invasive Group A Streptococcal Diseases and" exact="Viral" post="Respiratory Tract Infections. Frontiers in microbiology. 2016;7:342 Epub 2016/04/06."/>
 <result pre="The Association between Invasive Group A Streptococcal Diseases and Viral" exact="Respiratory" post="Tract Infections. Frontiers in microbiology. 2016;7:342 Epub 2016/04/06. 10.3389/fmicb.2016.0034227047460"/>
 <result pre="Association between Invasive Group A Streptococcal Diseases and Viral Respiratory" exact="Tract" post="Infections. Frontiers in microbiology. 2016;7:342 Epub 2016/04/06. 10.3389/fmicb.2016.0034227047460 4HerreraAL,"/>
 <result pre="10.1038/s41598-018-29714-x30108238 6OkamotoS, NagaseS. Pathogenic mechanisms of invasive group A Streptococcus" exact="infections" post="by influenza virus-group A Streptococcus superinfection. Microbiology and immunology."/>
 <result pre="capsule is required for adhesion of bacteria to virus-infected alveolar" exact="epithelial" post="cells and lethal bacterial-viral superinfection. Infection and immunity. 2004;72(10):6068–75."/>
 <result pre="bacteria to virus-infected alveolar epithelial cells and lethal bacterial-viral superinfection." exact="Infection" post="and immunity. 2004;72(10):6068–75. Epub 2004/09/24. 10.1128/IAI.72.10.6068-6075.200415385511 8OkamotoS, KawabataS, NakagawaI,"/>
 <result pre="A virus-infected hosts boost an invasive type of Streptococcus pyogenes" exact="infection" post="in mice. Journal of virology. 2003;77(7):4104–12. Epub 2003/03/14. 10.1128/jvi.77.7.4104-4112.200312634369"/>
 <result pre="10.1128/jvi.77.7.4104-4112.200312634369 9Weeks-GorospeJN, HurtigHR, IversonAR, SchunemanMJ, WebbyRJ, McCullersJA, et al.Naturally occurring" exact="swine influenza" post="A virus PB1-F2 phenotypes that contribute to superinfection with"/>
 <result pre="A virus PB1-F2 phenotypes that contribute to superinfection with Gram-positive" exact="respiratory" post="pathogens. Journal of virology. 2012;86(17):9035–43. Epub 2012/06/08. 10.1128/JVI.00369-1222674997 10OkamotoS,"/>
 <result pre="GierB VB, WoudtSHS, van SorgeNM, van AstenL. Associations between common" exact="respiratory" post="viruses and invasive group A streptococcal infection: A time-series"/>
 <result pre="group A streptococcal infection: A time-series analysis. Influenza and other" exact="respiratory" post="viruses. 2019;2019 Sep;13(5):453–458. 10.1111/irv.12658 Epub 2019 Jun 25. 31237087"/>
 <result pre="LouieJK, GlaserCA, HarrimanK, HackerJK, ArankiF, et al.Invasive group A streptococcal" exact="infection" post="concurrent with 2009 H1N1 influenza. Clinical infectious diseases: an"/>
 <result pre="group A streptococcal infection concurrent with 2009 H1N1 influenza. Clinical" exact="infectious" post="diseases: an official publication of theInfectious Diseases Society of"/>
 <result pre="H1N1 influenza. Clinical infectious diseases: an official publication of theInfectious" exact="Diseases" post="Society of America. 2010;50(10):e59–62. Epub 2010/04/10. 10.1086/652291 .20377405 14ScaberJ,"/>
 <result pre=".20377405 14ScaberJ, SaeedS, IhekweazuC, EfstratiouA, McCarthyN, O'MooreE. Group A streptococcal" exact="infections" post="during the seasonal influenza outbreak 2010/11 in South East"/>
 <result pre="Euro surveillance: bulletin Europeen sur les maladies transmissibles = European" exact="communicable disease" post="bulletin. 2011;16(5). Epub 2011/02/15. .21315058 15OlsenRJ, AshrafM, GonulalVE, AyerasAA,"/>
 <result pre="surveillance: bulletin Europeen sur les maladies transmissibles = European communicable" exact="disease" post="bulletin. 2011;16(5). Epub 2011/02/15. .21315058 15OlsenRJ, AshrafM, GonulalVE, AyerasAA,"/>
 <result pre="2011/02/15. .21315058 15OlsenRJ, AshrafM, GonulalVE, AyerasAA, CantuC, SheaPR, et al.Lower" exact="respiratory" post="tract infection in cynomolgus macaques (Macaca fascicularis) infected with"/>
 <result pre="15OlsenRJ, AshrafM, GonulalVE, AyerasAA, CantuC, SheaPR, et al.Lower respiratory tract" exact="infection" post="in cynomolgus macaques (Macaca fascicularis) infected with group A"/>
 <result pre="GregsonD, et al.Clinical and epidemiologic features of group a streptococcal" exact="pneumonia" post="in Ontario, Canada. Archives of internal medicine. 2003;163(4):467–72. Epub"/>
 <result pre="streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and" exact="diphtheria" post="toxoid-specific antibodies to protection. The Journal of infectious diseases."/>
 <result pre="J8- and diphtheria toxoid-specific antibodies to protection. The Journal of" exact="infectious diseases." post="2003;187(10):1598–608. Epub 2003/05/02. 10.1086/374800 .12721940 18BrandtER, TehT, RelfWA, HobbRI,"/>
 <result pre="Australian aboriginal isolates and reference strains of group A streptococci." exact="Infection" post="and immunity. 2000;68(12):6587–94. Epub 2000/11/18. 10.1128/iai.68.12.6587-6594.200011083769 19BronzeMS, CourtneyHS, DaleJB."/>
 <result pre="the group A streptococcal M protein elicits heterologous opsonic antibodies." exact="Infection" post="and immunity. 2002;70(5):2734–8. Epub 2002/04/16. 10.1128/iai.70.5.2734-2738.200211953422 21HallMA, StroopSD, HuMC,"/>
 <result pre="group A streptococcal vaccines protects mice against intranasal challenge infections." exact="Infection" post="and immunity. 2004;72(5):2507–12. Epub 2004/04/23. 10.1128/iai.72.5.2507-2512.200415102757 22KotloffKL, CorrettiM, PalmerK,"/>
 <result pre="and immunogenicity of 26-valent group a streptococcus vaccine in healthy" exact="adult" post="volunteers. Clinical infectious diseases: an official publication of the"/>
 <result pre="26-valent group a streptococcus vaccine in healthy adult volunteers. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="adult volunteers. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2005;41(8):1114–22. Epub 2005/09/16. 10.1086/444458 .16163629"/>
 <result pre="volunteers. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2005;41(8):1114–22. Epub 2005/09/16. 10.1086/444458 .16163629 24KlonoskiJM,"/>
 <result pre="in a mouse model of invasive group A streptococcal disease." exact="Infection" post="and immunity. 2000;68(11):6384–90. Epub 2000/10/18. 10.1128/iai.68.11.6384-6390.200011035749 26TwetenRK, HotzeEM, WadeKR."/>
 <result pre="2000/10/18. 10.1128/iai.68.11.6384-6390.200011035749 26TwetenRK, HotzeEM, WadeKR. The Unique Molecular Choreography of" exact="Giant" post="Pore Formation by the Cholesterol-Dependent Cytolysins of Gram-Positive Bacteria."/>
 <result pre="of Influenza Virus Hemagglutinin and Host Immune Responses Toward the" exact="Severity of" post="Influenza Virus: Streptococcus pyogenes Superinfections. Viral immunology. 2018;31(6):457–69. Epub"/>
 <result pre="Responses Toward the Severity of Influenza Virus: Streptococcus pyogenes Superinfections." exact="Viral" post="immunology. 2018;31(6):457–69. Epub 2018/06/06. 10.1089/vim.2017.019329870311 34ReedLJ. MH. A simple"/>
 <result pre="and characterization of the first cholesterol-dependent cytolysins from Gram-negative bacteria." exact="Infection" post="and immunity. 2013;81(1):216–25. Epub 2012/11/02. 10.1128/IAI.00927-1223115036 36BhakdiS, Tranum-JensenJ, SziegoleitA."/>
 <result pre="10.1128/IAI.00927-1223115036 36BhakdiS, Tranum-JensenJ, SziegoleitA. Mechanism of membrane damage by streptolysin-O." exact="Infection" post="and immunity. 1985;47(1):52–60. Epub 1985/01/01. 3880730 37TimmerAM, TimmerJC, PenceMA,"/>
 <result pre="the cytolytic activity of streptolysin S from group A streptococci." exact="Infection" post="and immunity. 2002;70(4):2166–70. Epub 2002/03/16. 10.1128/iai.70.4.2166-2170.200211895983 44Rivera-HernandezT, CarnathanDG, JonesS,"/>
 <result pre="MoylePM, et al.An Experimental Group A Streptococcus Vaccine That Reduces" exact="Pharyngitis" post="and Tonsillitis in a Nonhuman Primate Model. mBio. 2019;10(2)."/>
 <result pre="al.An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and" exact="Tonsillitis" post="in a Nonhuman Primate Model. mBio. 2019;10(2). Epub 2019/05/02."/>
 <result pre="BergholmAM, NorgrenM. Aspects of pathogenesis of serious group A streptococcal" exact="infections" post="in Sweden, 1988–1989. The Journal of infectious diseases. 1992;166(1):31–7."/>
 <result pre="group A streptococcal infections in Sweden, 1988–1989. The Journal of" exact="infectious diseases." post="1992;166(1):31–7. Epub 1992/07/01. 10.1093/infdis/166.1.31 .1607705 46Norrby-TeglundA, PauksensK, HolmSE, NorgrenM."/>
 <result pre="streptococcal mitogens and serious manifestation of disease. The Journal of" exact="infectious diseases." post="1994;170(3):585–91. Epub 1994/09/01. 10.1093/infdis/170.3.585 .8077715 47Norrby-TeglundA, KaulR, LowDE, McGeerA,"/>
 <result pre="the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G." exact="Infection" post="and immunity. 1996;64(12):5395–8. Epub 1996/12/01. 8945593 48MehtaS, McGeerA, LowDE,"/>
 <result pre="al.Morbidity and mortality of patients with invasive group A streptococcal" exact="infections" post="admitted to the ICU. Chest. 2006;130(6):1679–86. Epub 2006/12/15. 10.1378/chest.130.6.1679"/>
 <result pre="et al.Plasma from patients with severe invasive group A streptococcal" exact="infections" post="treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T"/>
 <result pre="G against streptococcal and staphylococcal superantigens: implications for therapy of" exact="toxic shock syndrome." post="Clinical infectious diseases: an official publication of theInfectious Diseases"/>
 <result pre="staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clinical" exact="infectious" post="diseases: an official publication of theInfectious Diseases Society of"/>
 <result pre="shock syndrome. Clinical infectious diseases: an official publication of theInfectious" exact="Diseases" post="Society of America. 2004;38(6):836–42. Epub 2004/03/05. 10.1086/381979 .14999628 51CawleyMJ,"/>
 <result pre="GuildayRE, BraxtonGR, et al.Intravenous immunoglobulin as adjunctive treatment for streptococcal" exact="toxic shock syndrome" post="associated with necrotizing fasciitis: case report and review. Pharmacotherapy."/>
 <result pre="et al.Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock" exact="syndrome" post="associated with necrotizing fasciitis: case report and review. Pharmacotherapy."/>
 <result pre="of IVIG therapy for severe invasive group A streptococcal infections." exact="Infection" post="and immunity. 1998;66(5):2279–83. Epub 1998/05/09. 9573118 53KaulR, McGeerA, Norrby-TeglundA,"/>
 <result pre="Norrby-TeglundA, KotbM, SchwartzB, O'RourkeK, et al.Intravenous immunoglobulin therapy for streptococcal" exact="toxic shock" post="syndrome—a comparative observational study. The Canadian Streptococcal Study Group."/>
 <result pre="syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="Study Group. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 1999;28(4):800–7. Epub 2000/05/29. 10.1086/515199 .10825042"/>
 <result pre="Group. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 1999;28(4):800–7. Epub 2000/05/29. 10.1086/515199 .10825042 54ParksT,"/>
 <result pre="SriskandanS. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic" exact="Shock" post="Syndrome: A Systematic Review and Meta-analysis. Clinical infectious diseases:"/>
 <result pre="Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="and Meta-analysis. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2018;67(9):1434–6. Epub 2018/05/23. 10.1093/cid/ciy40129788397 55AlejandriaMM,"/>
 <result pre="Meta-analysis. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2018;67(9):1434–6. Epub 2018/05/23. 10.1093/cid/ciy40129788397 55AlejandriaMM, LansangMA,"/>
 <result pre="DansLF, MantaringJB3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and" exact="septic shock." post="The Cochrane database of systematic reviews. 2013;(9):Cd001090 Epub 2013/09/18."/>
 <result pre="Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="US Hospitals. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2017;64(7):877–85. Epub 2016/12/31. 10.1093/cid/ciw87128034881 57Norrby-TeglundA,"/>
 <result pre="Hospitals. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2017;64(7):877–85. Epub 2016/12/31. 10.1093/cid/ciw87128034881 57Norrby-TeglundA, BasmaH,"/>
 <result pre="of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="therapeutic efficacy. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 1998;26(3):631–8. Epub 1998/04/03. 10.1086/514588 .9524835"/>
 <result pre="efficacy. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 1998;26(3):631–8. Epub 1998/04/03. 10.1086/514588 .9524835 58ReglinskiM,"/>
 <result pre="for the Use of Monoclonal Antibodies in the Treatment of" exact="Bacterial Infections." post="Antibodies. 2018;7(5). 61KawabataS, KunitomoE, TeraoY, NakagawaI, KikuchiK, TotsukaK, et"/>
 <result pre="induce protective immune responses against Streptococcus pyogenes challenge in mice." exact="Infection" post="and immunity. 2001;69(2):924–30. Epub 2001/02/13. 10.1128/IAI.69.2.924-930.200111159987 62HuangYS, FisherM, NasrawiZ,"/>
 <result pre="passive vaccination with the streptococcal hemoprotein receptor. The Journal of" exact="infectious diseases." post="2011;203(11):1595–601. Epub 2011/05/20. 10.1093/infdis/jir14921592989 63ZabriskieJB, Poon-KingT, BlakeMS, MichonF, YoshinagaM."/>
 <result pre="immunizations with the streptococcal esterase Sse protect mice against subcutaneous" exact="infection" post="with group A streptococci. Infection and immunity. 2007;75(7):3651–7. Epub"/>
 <result pre="Sse protect mice against subcutaneous infection with group A streptococci." exact="Infection" post="and immunity. 2007;75(7):3651–7. Epub 2007/05/16. 10.1128/IAI.00038-0717502395 68ZeppaJJ, KasperKJ, MohorovicI,"/>
 <result pre="Epub 2007/05/16. 10.1128/IAI.00038-0717502395 68ZeppaJJ, KasperKJ, MohorovicI, MazzucaDM, HaeryfarSMM, McCormickJK. Nasopharyngeal" exact="infection" post="by Streptococcus pyogenes requires superantigen-responsive Vbeta-specific T cells. Proceedings"/>
 <result pre="States of America. 2017 Epub 2017/08/11. 10.1073/pnas.170085811428794279 69BessenD, FischettiVA. Passive" exact="acquired" post="mucosal immunity to group A streptococci by secretory immunoglobulin"/>
 <result pre="passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent" exact="infection" post="of murine nasal mucosa-associated lymphoid tissue, a functional homologue"/>
 <result pre="nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils." exact="Infection" post="and immunity. 2005;73(12):7878–86. Epub 2005/11/22. 10.1128/IAI.73.12.7878-7886.200516299278 71ShapiroSZ. Lessons for"/>
 <result pre="of Haemophilus influenzae type b vaccination failure. The Journal of" exact="infectious diseases." post="1992;165Suppl 1:S121–8. Epub 1992/06/01. 10.1093/infdis/165-supplement_1-s121 .1588145 74OligbuG, HsiaY, FolgoriL,"/>
</results>
